Cargando…

The gut microbiome as a target for regulatory T cell-based immunotherapy: induction of regulatory lymphocytes by oral administration of anti-LPS enriched colostrum alleviates immune mediated colitis

BACKGROUND: Gut-derived bacterial endotoxin is an important cofactor in the pathogenesis of IBD. Regulatory T cells (Tregs) are essential for maintenance of peripheral tolerance and can prevent and alleviate IBD. To determine the immune modulatory effect of anti-LPS enriched hyperimmune colostrum, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Yaʼacov, Ami Ben, Lichtenstein, Yoav, Zolotarov, Lidya, Ilan, Yaron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628342/
https://www.ncbi.nlm.nih.gov/pubmed/26518263
http://dx.doi.org/10.1186/s12876-015-0388-x
_version_ 1782398434326609920
author Yaʼacov, Ami Ben
Lichtenstein, Yoav
Zolotarov, Lidya
Ilan, Yaron
author_facet Yaʼacov, Ami Ben
Lichtenstein, Yoav
Zolotarov, Lidya
Ilan, Yaron
author_sort Yaʼacov, Ami Ben
collection PubMed
description BACKGROUND: Gut-derived bacterial endotoxin is an important cofactor in the pathogenesis of IBD. Regulatory T cells (Tregs) are essential for maintenance of peripheral tolerance and can prevent and alleviate IBD. To determine the immune modulatory effect of anti-LPS enriched hyperimmune colostrum, its ability to induce Tregs and alleviate immune mediated colitis. METHODS: Immune-mediated colitis was induced in mice by intra-colonic instillation of Trinitrobenzene Sulfonate (TNBS). Four groups of mice were orally administered with two dosages of IgG-enriched colostrum fractions. The fractions were harvested from cows immunized against LPS derived from intestinal Escherichia coli bacteria (Imm124E). Control mice received non-immunized colostrum or vehicle (PBS). Treatment was administered one day following sensitization and four additional days following the administration of TNBS. The following parameters in the mice were tracked: body weight, bowel histology, serum cytokine levels and regulatory T cells. RESULTS: Oral administration of Imm124E hyperimmune colostrum ameliorated immune-mediated colitis. Significant amelioration of weight reduction was noted in treated mice. Oral administration of Imm124E improved bowel histology. Both the extent of the disease, inflammation score, and colitis damage and regeneration scores decreased in Imm-124E treated animals. These effects were associated with an increase in serum IL10 anti inflammatory cytokine levels, and an increase in CD4 + CD25+ and CD4 + Foxp3+ Tregs. CONCLUSIONS: Oral administration of Imm124E promoted Tregs and alleviated bowel inflammation in immune mediated colitis. The present data suggests that the microbiome may serve as a target for Tregs-based immunotherapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12876-015-0388-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4628342
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46283422015-11-01 The gut microbiome as a target for regulatory T cell-based immunotherapy: induction of regulatory lymphocytes by oral administration of anti-LPS enriched colostrum alleviates immune mediated colitis Yaʼacov, Ami Ben Lichtenstein, Yoav Zolotarov, Lidya Ilan, Yaron BMC Gastroenterol Research Article BACKGROUND: Gut-derived bacterial endotoxin is an important cofactor in the pathogenesis of IBD. Regulatory T cells (Tregs) are essential for maintenance of peripheral tolerance and can prevent and alleviate IBD. To determine the immune modulatory effect of anti-LPS enriched hyperimmune colostrum, its ability to induce Tregs and alleviate immune mediated colitis. METHODS: Immune-mediated colitis was induced in mice by intra-colonic instillation of Trinitrobenzene Sulfonate (TNBS). Four groups of mice were orally administered with two dosages of IgG-enriched colostrum fractions. The fractions were harvested from cows immunized against LPS derived from intestinal Escherichia coli bacteria (Imm124E). Control mice received non-immunized colostrum or vehicle (PBS). Treatment was administered one day following sensitization and four additional days following the administration of TNBS. The following parameters in the mice were tracked: body weight, bowel histology, serum cytokine levels and regulatory T cells. RESULTS: Oral administration of Imm124E hyperimmune colostrum ameliorated immune-mediated colitis. Significant amelioration of weight reduction was noted in treated mice. Oral administration of Imm124E improved bowel histology. Both the extent of the disease, inflammation score, and colitis damage and regeneration scores decreased in Imm-124E treated animals. These effects were associated with an increase in serum IL10 anti inflammatory cytokine levels, and an increase in CD4 + CD25+ and CD4 + Foxp3+ Tregs. CONCLUSIONS: Oral administration of Imm124E promoted Tregs and alleviated bowel inflammation in immune mediated colitis. The present data suggests that the microbiome may serve as a target for Tregs-based immunotherapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12876-015-0388-x) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-30 /pmc/articles/PMC4628342/ /pubmed/26518263 http://dx.doi.org/10.1186/s12876-015-0388-x Text en © Yaʼacov et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Yaʼacov, Ami Ben
Lichtenstein, Yoav
Zolotarov, Lidya
Ilan, Yaron
The gut microbiome as a target for regulatory T cell-based immunotherapy: induction of regulatory lymphocytes by oral administration of anti-LPS enriched colostrum alleviates immune mediated colitis
title The gut microbiome as a target for regulatory T cell-based immunotherapy: induction of regulatory lymphocytes by oral administration of anti-LPS enriched colostrum alleviates immune mediated colitis
title_full The gut microbiome as a target for regulatory T cell-based immunotherapy: induction of regulatory lymphocytes by oral administration of anti-LPS enriched colostrum alleviates immune mediated colitis
title_fullStr The gut microbiome as a target for regulatory T cell-based immunotherapy: induction of regulatory lymphocytes by oral administration of anti-LPS enriched colostrum alleviates immune mediated colitis
title_full_unstemmed The gut microbiome as a target for regulatory T cell-based immunotherapy: induction of regulatory lymphocytes by oral administration of anti-LPS enriched colostrum alleviates immune mediated colitis
title_short The gut microbiome as a target for regulatory T cell-based immunotherapy: induction of regulatory lymphocytes by oral administration of anti-LPS enriched colostrum alleviates immune mediated colitis
title_sort gut microbiome as a target for regulatory t cell-based immunotherapy: induction of regulatory lymphocytes by oral administration of anti-lps enriched colostrum alleviates immune mediated colitis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628342/
https://www.ncbi.nlm.nih.gov/pubmed/26518263
http://dx.doi.org/10.1186/s12876-015-0388-x
work_keys_str_mv AT yaʼacovamiben thegutmicrobiomeasatargetforregulatorytcellbasedimmunotherapyinductionofregulatorylymphocytesbyoraladministrationofantilpsenrichedcolostrumalleviatesimmunemediatedcolitis
AT lichtensteinyoav thegutmicrobiomeasatargetforregulatorytcellbasedimmunotherapyinductionofregulatorylymphocytesbyoraladministrationofantilpsenrichedcolostrumalleviatesimmunemediatedcolitis
AT zolotarovlidya thegutmicrobiomeasatargetforregulatorytcellbasedimmunotherapyinductionofregulatorylymphocytesbyoraladministrationofantilpsenrichedcolostrumalleviatesimmunemediatedcolitis
AT ilanyaron thegutmicrobiomeasatargetforregulatorytcellbasedimmunotherapyinductionofregulatorylymphocytesbyoraladministrationofantilpsenrichedcolostrumalleviatesimmunemediatedcolitis
AT yaʼacovamiben gutmicrobiomeasatargetforregulatorytcellbasedimmunotherapyinductionofregulatorylymphocytesbyoraladministrationofantilpsenrichedcolostrumalleviatesimmunemediatedcolitis
AT lichtensteinyoav gutmicrobiomeasatargetforregulatorytcellbasedimmunotherapyinductionofregulatorylymphocytesbyoraladministrationofantilpsenrichedcolostrumalleviatesimmunemediatedcolitis
AT zolotarovlidya gutmicrobiomeasatargetforregulatorytcellbasedimmunotherapyinductionofregulatorylymphocytesbyoraladministrationofantilpsenrichedcolostrumalleviatesimmunemediatedcolitis
AT ilanyaron gutmicrobiomeasatargetforregulatorytcellbasedimmunotherapyinductionofregulatorylymphocytesbyoraladministrationofantilpsenrichedcolostrumalleviatesimmunemediatedcolitis